Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Taxane-associated Acute Pain Syndrome With Etoricoxib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age ≥18 years~* Stage I-III breast cancer~* ECOG 0-2~* Received docetaxel-containing chemotherapy~Exclusion Criteria:~* Existed any chronic pain or peripheral neuropathy~* Prior history of gastrointestinal bleeding or ulcer~* Long-term history of receiving oral corticoids, nonsteroid anti-inflammatory drugs (NSAIDs) or anti-histamines~* Allergies to NSAIDs or aspirin~* Blood creatinine level exceeds 1.5 times of the upper limit of normal range

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Etoricoxib (Type: EXPERIMENTAL): Prophylactic etoricoxib (60 mg) was administered orally at each course of docetaxel-containing chemotherapy, which started from the day of chemotherapy and was performed once per day for 8 days (day 1-8).
- Control (Type: NO_INTERVENTION): No prophylactic regimen was given.

Based on this trial design, predict the completion outcome and termination type (if applicable).